Pramipexole: Augmentation in the treatment of depressive symptoms

CNS Spectrums

Volumn 11, Issue 3, 2006, Pages 172-175

  Gupta, Sanjay ^a,b   Vincent, Jennifer L ^c   Frank, Bradford ^d,e  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b Olean General Hospital   (United States)

^c Cattaraugus County Continuing Day Treatment Program   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e WCA Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; ESCITALOPRAM; LITHIUM CARBONATE; NORTRIPTYLINE; OLANZAPINE; PRAMIPEXOLE; RISPERIDONE; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; CASE REPORT; DEPRESSION; DEPRESSIVE SYMPTOM; DIZZINESS; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; OFF LABEL DRUG USE; PRIORITY JOURNAL; SYMPTOM;

EID: 33645240742     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014280     Document Type: Article

References (23)

1. Calabrese JR, Hirshfield RM, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin. Psychiatry. 2003;64:425-432.
2. Keck PE Jr, Mc Elroy SL, Arnold SL Bipolar disorder. Med Clin North Am. 2001;85:645-661.
3. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6:127-137.
4. Rihmer Z, Pestality P Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am. 1999;22:667-673.
5. Keck PE Jr, Nelson EB, McElroy SL. Advances in pharmacologic treatment of bipolar depression. Biol Psychiatry. 2003;53:671-679.
6. Muzina DJ, Calabrese JR. Recent placebo-controlled acute trials in bipolar depression: focus on methodology. Int J Neuropsychopharmacol. 2003;6:285-291.
7. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness and treatment options. Bipolar Disord. 2003:5:85-97.
8. Arndt J, Hyttel J, Overo KF. Prolonged treatment with the specific 5-HT inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm. 1984;36:221-230.
9. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405:365-373.
10. Maj J, Rogoz Z. Pharmacological effects of venlafaxine a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine, and serotonin systems. J Neural Transm. 1999;106:197-211.
11. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychophamacol. 1997;12(suppl3):S7-S14.
12. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59(suppl 5):60-63.
13. Black KJ, Hershey T, Koller JM, et al. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of D3-preferring dopamine agonist. Proc Natl Acad Sci USA. 1999:17113-17118.
14. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotions features of mood disorders. Curr Opin Neurobiol. 2001;11:240-249.
15. Carvey PM, McGuire SO, Ling ZT. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord. 2001;7:213-223.
16. Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54-60.
17. DeBattista C, Solvanson HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20:274-275.
18. Goldberg JF Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156:798.
19. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized double-blind placebo controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564-566.
20. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinsons disease. Clin Neuropharmacol. 1998;21:141-151.
21. Le WD, Jankowic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18:389-396.
22. Pramipexole hydrochloride [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc: 2005.
23. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34:137-141.